Clinical trials: Hepatocellular Carcinoma With Portal Vein Thrombosis
Hepatocellular Carcinoma
Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein
This is a two-arm, open-label, prospective, multi-center, randomized, active-controlled clinical trial to assess efficacy and safety of TheraSphere in comparison to standard of care therapy (sorafenib) in the treatment of…
- Trial name
- YES-P (NCT01887717)
- Testing
- TheraSphere®, Sorafenib
- Where
- 19 sites in United States, Belgium and 4 more
- Volunteers
- 36 people
- Sponsor
- Boston Scientific Corporation
Hepatocellular Carcinoma
TACE Combined With ICIs Plus MTT After 125I Irradiation Stent Placement in HCC With Main PVTT.
Hepatocellular carcinoma (HCC) patients with Vp4 [main trunk] portal vein tumor thrombosis (PVTT) face a significantly poor prognosis, and current treatment options provide limited benefits.
- Trial name
- NCT06669377
- Where
- China
- Volunteers
- 444 people
- Sponsor
- Zhongda Hospital
Carcinoma, Hepatocellular
Proteomic Analysis of Human Hepatocellular Carcinoma
This is a pilot study to evaluate the difference between the protein expression between hepatocellular carcinoma and tumor with vessel invasion in Asian patients with hepatocellular carcinoma.
- Trial name
- NCT01177631
- Testing
- Operation
- Where
- Taiwan
- Volunteers
- 5 people
- Sponsor
- Far Eastern Memorial Hospital
Hepatocellular Carcinoma
HAIC Plus Toripalimab vs. HAIC Plus Sorafenib for HCC With PVTT: a Non-comparative, Prospective, Randomized Trial
The purpose of this study is to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin plus toripalimab versus hepatic arterial infusion chemotherapy of…
- Trial name
- NCT04135690
- Testing
- Hepatic arterial infusion chemotherapy, Toripalimab, Sorafenib
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Sun Yat-sen University
HCC - Hepatocellular Carcinoma
Efficacy and Safety of Radiotherapy Combined With Tislelizumab and Anlotinib in the Treatment of Hepatocellular Carcinoma Complicated With Portal Vein Tumor Thrombus
For HCC patients with PVTT who the researchers believe can benefit from radiotherapy combined with tislelizumab and anlotinib, informed consent forms will be signed, and then they will receive the study treatment and be followed…
- Trial name
- NCT07363512
- Testing
- Radiotherapy combined with tislelizumab and anlotinib
- Volunteers
- 27 people
- Sponsor
- Henan Cancer Hospital
Hepatocellular Carcinoma, Hepatocellular Cancer
Atezolizumab Plus Bevacizumab Alone or Combined with External Beam Radiotherapy for HCC with Macrovascular Invasion
The recent global IMbrave150 study evaluated the combination of atezolizumab and bevacizumab versus sorafenib in 501 patients with advanced or metastatic Hepatocellular Carcinoma (HCC).
- Conditions
- Hepatocellular Carcinoma, Hepatocellular Cancer, Hepatocellular Carcinoma Non-resectable, Hepatocellular Carcinoma Stage IV
- Trial name
- ALERT-HCC (NCT05992220)
- Testing
- Atezolizumab plus bevacizumab, combined EBRT to vascular invasion, Atezolizumab plus bevacizumab
- Where
- South Korea
- Volunteers
- 138 people
- Sponsor
- Asan Medical Center
HepatoCellular Carcinoma
Radiotherapy in Hepatocellular Carcinomas After Hepatectomy With Narrow Margin (<1 cm) or Portal Vein Thrombosis
Hepatocellular carcinoma (HCC) is one of ten leading cancer types worldwide and also in Asia, but the five-year relative survival rate is relatively quite low1-3.
- Trial name
- RHCC (NCT02309788)
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Guangxi Medical University
Carcinoma, Hepatocellular
Pair Production PET Imaging to Detect Particle Distribution in Patients Undergoing Yttrium-90 Radioembolization
The primary goal of the study is to see if the PET/CT will be able to determine the precise location of the Y-90 particles within the liver and within the tumors.
- Trial name
- PET-Y90 (NCT02848638)
- Volunteers
- 35 people
- Sponsor
- University of Washington
Carcinoma. Hepatocellular
Effectiveness and Safety of the Simultaneous Radiotherapy and Hyperthermia After Transarterial Chemoembolization in Hepatocellular Carcinoma Patients Combined With Portal Vein Tumor Thrombosis
The presence of portal vein tumor thrombosis (PVTT)in patients with HCC is one of the most significant prognostic factors for poor prognosis, without treatment, their survival is less than 3 months.
- Trial name
- NCT01911000
- Testing
- RT and hyperthermia after TACE
- Where
- South Korea
- Volunteers
- 69 people
- Sponsor
- Samsung Medical Center
Hepatocellular Carcinoma
Radioembolization as a Spearhead Treatment of Hepatocellular Carcinoma With Localized Portal Vein Tumor Thrombosis
The RESOLVE trial, an open-label, single-arm, multi-center study, aims to assess the efficacy and safety of ablative radioembolization using TheraSphere Yttrium-90 microspheres.
- Trial name
- RESOLVE (NCT06166576)
- Testing
- Ablative radioembolization
- Where
- 5 sites in South Korea
- Volunteers
- 30 people
- Sponsor
- Seoul National University Hospital
Hepatocellular Carcinoma
Sorafenib Alone Versus Sorafenib Combined With HAIC for Advanced HCC
The purpose of this study is to evaluate the efficacy and safety of sorafenib combined with hepatic arterial infusion chemotherapy (HAIC) compared with sorafenib Alone in patients with hepatocellular carcinoma (HCC) with major…
- Trial name
- NCT02774187
- Testing
- Sorafenib, Hepatic arterial infusion chemotherapy, Folfox Protocol
- Where
- 5 sites in China
- Volunteers
- 247 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma, Portal Vein Tumor Thrombus
Stereotactic Ablative Radiotherapy for Hepatocellular Carcinoma With Major Portal Vein Invasion
Recently, several studies reported promising outcomes of patients after external beam radiotherapy (EBRT) for hepatocellular carcinoma (HCC) with portal vein tumor thrombosis.
- Trial name
- NCT01850368
- Testing
- Stereotactic ablative radiotherapy
- Where
- 8 sites in South Korea
- Volunteers
- 35 people
- Sponsor
- Korea Cancer Center Hospital
Hepatocellular Carcinoma With Major Portal Vein Thrombosis
Combination Therapy of HAIC and HLX10 and HLX04 in HCC With Major Portal Vein Tumor Thrombosis
This is a randomized, double-blinded, controlled, phase II study. The purpose is to evaluate efficacy and safety of the combination therapy of HAIC (Hepatic arterial infusion chemotherapy) with HLX10 (PD-1 antibody) and HLX04…
- Trial name
- NCT04947826
- Testing
- HAIC (Hepatic arterial infusion chemotherapy), HLX10 (PD-1 antibody), HLX04 (VEGF antibody)
- Volunteers
- 100 people
- Sponsor
- Shanghai Zhongshan Hospital
Liver Neoplasm, Portal Vein Tumor Thrombosis
Proton Beam Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis
The standard treatment of advanced hepatocellular carcinoma (HCC) is sorafenib. Though the agent showed clear survival benefit in two randomized phase III trials, the benefit was modest and response rate was just a few percent.
- Conditions
- Liver Neoplasm, Portal Vein Tumor Thrombosis, Proton Therapy
- Trial name
- PTHP (NCT02571946)
- Testing
- Proton beam therapy
- Where
- South Korea
- Volunteers
- 53 people
- Sponsor
- Samsung Medical Center
Portal Vein Tumor Thrombus
A Trial to Compare Surgery With Sorafenib for Hepatic Celluler Cancer With Portal Vein Tumor Thrombosis
According to the guidelines recommended, only a few new targeted therapy drugs treatment, such as Sorafenib, is proper. It's 3 year survival rate is only 8% or so.
- Trial name
- NCT03178656
- Testing
- Sorafenib, surgery
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Huazhong University of Science and Technology
Hepatocellular Carcinoma (HCC)
Outcome of Transarterial Chemo-embolization (TACE) in Hepatocellular Carcinoma Patients With Partial Portal Vein Thrombosis
Portal vein tumor invasion (PVT) is a common complication in HCC. the studyb Aimed to assess the outcomes after TACE in patients with branch PVT regarding Child classification, radiological response and 1 year survival.
- Trial name
- NCT03007212
- Testing
- transarterial chemoembolization versus the standard treatment with sorafinib
- Volunteers
- 30 people
- Sponsor
- Ain Shams University
Localized Resectable Adult Primary Liver Cancer, Stage III Childhood Liver Cancer
Surgery With or Without Hepatic Arterial Chemotherapy in Treating Patients With Liver Cancer
RATIONALE: Drugs used in chemotherapy, such as fluorouracil and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00238160
- Testing
- cisplatin, fluorouracil, adjuvant therapy
- Where
- 4 sites in Japan
- Sponsor
- Kyoto University
Carcinoma, Hepatocellular
Study of Folfox4 Chemotherapy Regimen to Prevent Early Postoperative Recurrence for HCC-PVTT Patients
This study is to investigate the efficacy and safety of Folfox4 chemotherapy regimen to prevent early recurrence for hepatocellular carcinoma patients with portal vein tumor thrombus following curative resection
- Trial name
- NCT02813096
- Testing
- folfox4 chemotherapy regimen
- Volunteers
- 500 people
- Sponsor
- Guangxi Medical University
Hepatocellular Carcinoma With Portal Vein Thrombosis
Non-selective Beta Blockers Versus EVL for Primary Prophylaxis of Esophageal Variceal Bleeding in Patients With Hepatocellular Carcinoma With Portal Vein Tumour Thrombosis.
Every patient with HCC (Hepato-Cellular Carcinoma) with main portal vein thrombosis will be screened for presence of large esophageal varices and will be randomized between non-selective beta blocker versus primary endoscopic…
- Trial name
- NCT01659346
- Testing
- Endoscopic Variceal Ligation, Carvedilol
- Where
- India
- Sponsor
- Institute of Liver and Biliary Sciences, India
Hepatocellular Carcinoma, Portal Vein Tumor Thrombosis
Safety and Efficacy of Radiotherapy Plus Sintilimab for HCC With Portal Vein Tumor Thrombosis
The proposed study is an open-label, single-center, single arm phase 1b study to evaluate the safety and efficacy of radiotherapy plus sintilimab for HCC with PVTT.
- Trial name
- NCT04104074
- Testing
- Radiotherapy, Sintilimab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Beijing Tsinghua Chang Gung Hospital